Nuvation Bio Inc.
NYSE:NUVB
Overview | Financials
| Company Name | Nuvation Bio Inc. |
| Symbol | NUVB |
| Currency | USD |
| Price | 3.49 |
| Market Cap | 1,194,532,770 |
| Dividend Yield | 0% |
| 52-week-range | 1.54 - 4.09 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. David T. Hung M.D. |
| Website | https://www.nuvationbio.com |
An error occurred while fetching data.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD






